NORGINE LIMITED PHARMACOVIGILANCE Agreement BetweenPharmacovigilance Agreement • March 18th, 2020 • England
This Agreement is supplemental to the Asset Purchase and Licence Agreement between Norgine B.V. and CMS dated 30th December 2014 for the Product referenced in Appendix 1 (the “Asset Purchase and Licence Agreement”) and replaces the Prior Agreement hereafter defined.
Pharmacovigilance Agreement for Elcitonin between AKP, AKPB, CMS HKCMS DMCC, and Shenzhen KangzhePharmacovigilance Agreement • February 21st, 2020
PRILIGY LICENSE AGREEMENT This License Agreement (hereinafter referred to as the “Agreement”) made and entered into as of this May 14, 2012. by and between GENUPRO, INC. a corporation organized under the laws of the State of North Carolina having its...Pharmacovigilance Agreement • August 7th, 2012 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • England
WHEREAS, LICENSOR and its Affiliates own or have licensed certain intellectual property related to the Product (as defined herein below),
AMENDMENT NO. 1 TO PHARMACOVIGILANCE AGREEMENTPharmacovigilance Agreement • June 22nd, 2021
Norgine Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, Middlesex UB9 6NS (hereinafter referred to as “NORGINE”).
PHARMACOVIGILANCE AGREEMENTPharmacovigilance Agreement • August 5th, 2020
This Pharmacovigilance Agreement (this “Agreement”) is made and entered into as of [DATE] by and between Gelesis, Inc., a Delaware corporation with a business address of 501 Boylston Street, Suite 6102, Boston, MA 02116, USA (“Gelesis”) and CMS Bridging DMSS, a company organized under the laws of the United Arab Emirates with a business address of Unit No.: 205B, JBC1, Plot No.: JLT-PH1-G2A, Jumeirah Lakes Towers, Dubai, United Arab Emirates (“CMS”) Gelesis and CMS may be referred to herein collectively as the “Parties” and individually as a “Party.”
NORGINE LIMITED PHARMACOVIGILANCE Agreement BetweenPharmacovigilance Agreement • March 4th, 2015 • England
This Agreement is supplemental to the Asset Purchase and Licence AgreementXXXXX Agreement dated DD MMM YYYY30 December 2014 for the Product referenced in Appendix 1 (the “Asset Purchase and Licence AgreementXXXXX Agreement”).
ONCOLOGY VENTURE ApS and R-PHARM US OPERATING, LLC DEVELOPMENT, OPTION AND LICENSE AGREEMENTPharmacovigilance Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
The first communication from Partner to R-Pharm US should be communicated in writing by email (and confirmed by fax) to the contact point of the Pharmacovigilance contact person of R-Pharm US.
Product Imdur (Isosorbide-5-mononitrate) Safety Agreement Last Updated NA Effective Date of Agreement DDMMYYY Version Number 1.0Pharmacovigilance Agreement • June 16th, 2016
PHARMACOVIGILANCE AGREEMENT by and between ASTRAZENECA AB and Everest Future Limited for Imdur® product, brand and associated assets
PHARMACOVIGILANCE AGREEMENT Between Neurelis, Inc.Pharmacovigilance Agreement • October 18th, 2020 • California
This Pharmacovigilance Agreement (“PVA”) is made and entered into with an effective date of DDMMYYYY between Neurelis, Inc. (“Neurelis”) and CMS (“CMS”) in order to comply with pharmacovigilance and regulatory responsibilities. Neurelis, Inc. and CMS may hereinafter be referred to individually as a “Party” or collectively as the “Parties”.
Pharmacovigilance Agreement for Elcitonin between AKP, AKPB, CMS Pharma, and KangzhePharmacovigilance Agreement • August 10th, 2018
